[Reverse remodeling -- paradigm shift in the treatment of pulmonary hypertension]

Dtsch Med Wochenschr. 2006 Apr 21;131(16):871-4. doi: 10.1055/s-2006-939860.

[Article in German]

Authors

H A Ghofrani¹, R T Schermuly, N Weissmann, W Seeger, F Grimminger

Affiliation

¹ Medizinische Klinik II/V, Universitätsklinikum Giessen und Marburg GmbH. ardeschir.ghofrani@innere.med.uni-giessen.de

PMID: 16625479
DOI: 10.1055/s-2006-939860

No abstract available

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Benzamides
Cell Division / drug effects
Drug Therapy, Combination
Endothelin-1 / antagonists & inhibitors
Endothelium, Vascular / drug effects
Fibromuscular Dysplasia / complications
Fibromuscular Dysplasia / drug therapy
Humans
Hypertension, Pulmonary / classification
Hypertension, Pulmonary / drug therapy*
Imatinib Mesylate
Muscle, Smooth, Vascular / drug effects
Phosphodiesterase Inhibitors / administration & dosage
Piperazines / administration & dosage
Prostaglandins / administration & dosage
Pulmonary Artery / drug effects
Pulmonary Artery / physiopathology
Pulmonary Disease, Chronic Obstructive / complications
Pulmonary Disease, Chronic Obstructive / drug therapy
Pulmonary Embolism / complications
Pulmonary Embolism / therapy
Pyrimidines / administration & dosage
Vasodilator Agents / administration & dosage

Substances

Benzamides
Endothelin-1
Phosphodiesterase Inhibitors
Piperazines
Prostaglandins
Pyrimidines
Vasodilator Agents
Imatinib Mesylate